Mrna therapeutic compositions and use to treat diseases and disorders
US-2016184458-A1 · Jun 30, 2016 · US
Composition for treating neuroinflammatory disease comprising complement component 8 gamma protein or fragment thereof
US11389506B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11389506-B2 |
| Application number | US-201917258707-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 7, 2019 |
| Priority date | Jul 20, 2018 |
| Publication date | Jul 19, 2022 |
| Grant date | Jul 19, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a composition for treating neuroinflammatory disease comprising a complement component 8 gamma protein or a fragment thereof, and more particularly, to use for treating neuroinflammatory disease of a complement component 8 gamma protein or a fragment thereof which exhibits an effect of reducing the expression of inflammatory cytokines in microglia.The composition of the present invention has effects of reducing Alzheimer's abnormal behavior patterns and reducing the secretion of neuroinflammatory cytokines in brain microglia and thus can be very usefully used for development of an agent for preventing or treating neuroinflammatory disease.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for reducing treating neuroinflammation, the method comprising administering an effective dose of a composition comprising a complement component 8-gamma protein having the amino acid sequence of SEQ ID NO: 1 as an active ingredient to a subject in need thereof. 2. The method of claim 1 , wherein the neuroinflammation is associated with a disease selected from the group consisting of Alzheimer's disease, Parkinson's disease, Niemann's disease, amyotrophic axonal sclerosis, multiple sclerosis, neuroblastoma, stroke, Lou Gehrig's disease, Huntington's disease, Creutzfeldt-Jakob disease, post-traumatic stress disorder, depression, schizophrenia, and spinal muscular atrophy. 3. The method of claim 1 , wherein the composition inhibits neuroinflammation by inhibiting the expression of inflammatory cytokines in microglia. 4. The method of claim 1 , wherein the composition is a pharmaceutical composition.
Assignees
Inventors
Classifications
Adding ingredients (adding preservatives A23B70/10) · CPC title
- A61K38/1725Primary
Complement proteins, e.g. anaphylatoxin, C3a or C5a · CPC title
Murine · CPC title
Animals treated with compounds which are neither proteins nor nucleic acids · CPC title
Food compositions, function of food ingredients or processes for food or foodstuffs · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11389506B2 cover?
- The present invention relates to a composition for treating neuroinflammatory disease comprising a complement component 8 gamma protein or a fragment thereof, and more particularly, to use for treating neuroinflammatory disease of a complement component 8 gamma protein or a fragment thereof which exhibits an effect of reducing the expression of inflammatory cytokines in microglia.The compositio…
- Who is the assignee on this patent?
- Kyungpook Nat Univ Ind Academic Coop Found
- What technology area does this patent fall under?
- Primary CPC classification A61K38/1725. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jul 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).